Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients

Iris Navarro-Millán, Lang Chen, Jeffrey D. Greenberg, Dimitrios A. Pappas, Jeffrey R. Curtis

Research output: Contribution to journalArticle

Abstract

Objective: To determine the prevalence and persistence of new-onset clinical remission in rheumatoid arthritis (RA) patients. Methods: The Consortium of Rheumatology Researchers of North America (CORRONA) cohort was used to examine the prevalence of remission and associated comorbidities and RA therapies according to the 2011 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) remission criteria. Factors influencing the likelihood of remaining in remission were identified by logistic regression with generalized estimating equations. Analysis of variance and Tukey's test were used to determine differences in disability according to whether RA patients had been in remission or only low disease activity (LDA). Results: A total of 2105 individuals met ACR/EULAR remission criteria at the most recent visit within CORRONA, yielding an 8% point prevalence of remission. Patients with certain comorbidities (e.g., heart failure) were significantly less likely to achieve or remain in remission compared to those without these conditions ( p <0.001 for each). Among prednisone users, the prevalence of remission was 1-6% (depending on dose) higher compared to those not on prednisone (10%). More than 50% of patients who had consistently been in remission for ≥1 year were able to remain in remission over the next year. Patients consistently in remission had less disability than patients who achieved LDA or who fluctuated between remission and LDA. Conclusion: Patients consistently in remission for at least 1 year had a high likelihood to remain in remission. These individuals might be considered the most likely candidates for de-escalation or withdrawal of RA treatments.

Original languageEnglish (US)
Pages (from-to)137-143
Number of pages7
JournalSeminars in Arthritis and Rheumatism
Volume43
Issue number2
DOIs
StatePublished - Oct 2013
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
Rheumatology
North America
Prednisone
Comorbidity
Research Personnel
Rheumatic Diseases
Analysis of Variance
Heart Failure
Logistic Models
Therapeutics

Keywords

  • CRP
  • Remission
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Anesthesiology and Pain Medicine

Cite this

Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients. / Navarro-Millán, Iris; Chen, Lang; Greenberg, Jeffrey D.; Pappas, Dimitrios A.; Curtis, Jeffrey R.

In: Seminars in Arthritis and Rheumatism, Vol. 43, No. 2, 10.2013, p. 137-143.

Research output: Contribution to journalArticle

Navarro-Millán, Iris ; Chen, Lang ; Greenberg, Jeffrey D. ; Pappas, Dimitrios A. ; Curtis, Jeffrey R. / Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients. In: Seminars in Arthritis and Rheumatism. 2013 ; Vol. 43, No. 2. pp. 137-143.
@article{1ab5a66a28264a90b85aecbd450a2ed3,
title = "Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients",
abstract = "Objective: To determine the prevalence and persistence of new-onset clinical remission in rheumatoid arthritis (RA) patients. Methods: The Consortium of Rheumatology Researchers of North America (CORRONA) cohort was used to examine the prevalence of remission and associated comorbidities and RA therapies according to the 2011 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) remission criteria. Factors influencing the likelihood of remaining in remission were identified by logistic regression with generalized estimating equations. Analysis of variance and Tukey's test were used to determine differences in disability according to whether RA patients had been in remission or only low disease activity (LDA). Results: A total of 2105 individuals met ACR/EULAR remission criteria at the most recent visit within CORRONA, yielding an 8{\%} point prevalence of remission. Patients with certain comorbidities (e.g., heart failure) were significantly less likely to achieve or remain in remission compared to those without these conditions ( p <0.001 for each). Among prednisone users, the prevalence of remission was 1-6{\%} (depending on dose) higher compared to those not on prednisone (10{\%}). More than 50{\%} of patients who had consistently been in remission for ≥1 year were able to remain in remission over the next year. Patients consistently in remission had less disability than patients who achieved LDA or who fluctuated between remission and LDA. Conclusion: Patients consistently in remission for at least 1 year had a high likelihood to remain in remission. These individuals might be considered the most likely candidates for de-escalation or withdrawal of RA treatments.",
keywords = "CRP, Remission, Rheumatoid arthritis",
author = "Iris Navarro-Mill{\'a}n and Lang Chen and Greenberg, {Jeffrey D.} and Pappas, {Dimitrios A.} and Curtis, {Jeffrey R.}",
year = "2013",
month = "10",
doi = "10.1016/j.semarthrit.2013.02.002",
language = "English (US)",
volume = "43",
pages = "137--143",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients

AU - Navarro-Millán, Iris

AU - Chen, Lang

AU - Greenberg, Jeffrey D.

AU - Pappas, Dimitrios A.

AU - Curtis, Jeffrey R.

PY - 2013/10

Y1 - 2013/10

N2 - Objective: To determine the prevalence and persistence of new-onset clinical remission in rheumatoid arthritis (RA) patients. Methods: The Consortium of Rheumatology Researchers of North America (CORRONA) cohort was used to examine the prevalence of remission and associated comorbidities and RA therapies according to the 2011 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) remission criteria. Factors influencing the likelihood of remaining in remission were identified by logistic regression with generalized estimating equations. Analysis of variance and Tukey's test were used to determine differences in disability according to whether RA patients had been in remission or only low disease activity (LDA). Results: A total of 2105 individuals met ACR/EULAR remission criteria at the most recent visit within CORRONA, yielding an 8% point prevalence of remission. Patients with certain comorbidities (e.g., heart failure) were significantly less likely to achieve or remain in remission compared to those without these conditions ( p <0.001 for each). Among prednisone users, the prevalence of remission was 1-6% (depending on dose) higher compared to those not on prednisone (10%). More than 50% of patients who had consistently been in remission for ≥1 year were able to remain in remission over the next year. Patients consistently in remission had less disability than patients who achieved LDA or who fluctuated between remission and LDA. Conclusion: Patients consistently in remission for at least 1 year had a high likelihood to remain in remission. These individuals might be considered the most likely candidates for de-escalation or withdrawal of RA treatments.

AB - Objective: To determine the prevalence and persistence of new-onset clinical remission in rheumatoid arthritis (RA) patients. Methods: The Consortium of Rheumatology Researchers of North America (CORRONA) cohort was used to examine the prevalence of remission and associated comorbidities and RA therapies according to the 2011 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) remission criteria. Factors influencing the likelihood of remaining in remission were identified by logistic regression with generalized estimating equations. Analysis of variance and Tukey's test were used to determine differences in disability according to whether RA patients had been in remission or only low disease activity (LDA). Results: A total of 2105 individuals met ACR/EULAR remission criteria at the most recent visit within CORRONA, yielding an 8% point prevalence of remission. Patients with certain comorbidities (e.g., heart failure) were significantly less likely to achieve or remain in remission compared to those without these conditions ( p <0.001 for each). Among prednisone users, the prevalence of remission was 1-6% (depending on dose) higher compared to those not on prednisone (10%). More than 50% of patients who had consistently been in remission for ≥1 year were able to remain in remission over the next year. Patients consistently in remission had less disability than patients who achieved LDA or who fluctuated between remission and LDA. Conclusion: Patients consistently in remission for at least 1 year had a high likelihood to remain in remission. These individuals might be considered the most likely candidates for de-escalation or withdrawal of RA treatments.

KW - CRP

KW - Remission

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84886100878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886100878&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2013.02.002

DO - 10.1016/j.semarthrit.2013.02.002

M3 - Article

VL - 43

SP - 137

EP - 143

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 2

ER -